Q2 2025 Zevra Therapeutics Inc Earnings Call Transcript

Aug 12, 2025 / 08:30 PM GMT

Release Date Price: $11.76 (+0.51%)

Transcript 10-Q8-K

Key Points

Positve

Zevra Therapeutics Inc (ZVRA) reported a strong Q2 net revenue of $25.9 million, reflecting robust demand and effective operational execution.
The company completed the sale of its PRV for $150 million, significantly strengthening its balance sheet.
Zevra Therapeutics Inc (ZVRA) submitted a marketing authorization application for its product in Europe, marking a key milestone in its geographic expansion.
The US launch of MyFIFA, a treatment for Niemann-Pick disease type C, has been successful, with 129 prescription forms received by the end of Q2.
The company has a solid cash position with $217.7 million in cash equivalents and investments, providing financial flexibility for future initiatives.

Negative

The launch of OProva, a treatment for urea cycle disorders, has seen limited pull-through with only one prescription enrollment form in Q2.
Zevra Therapeutics Inc (ZVRA) recognized a non-cash charge of $58.7 million for impairment of intangible assets and an inventory write-down of $11.7 million.
Operating expenses increased to $24.2 million, partly due to professional fees related to a proxy contest and commercial activities.
The company faces challenges in increasing diagnosis and treatment access for undiagnosed patients with Niemann-Pick disease type C.
Adoption of OProva continues to be slow, and the company remains cautious about its market performance.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ZVRA.OQ - Zevra Therapeutics Inc
Q2 2025 Zevra Therapeutics Inc Earnings Call
Aug 12, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Mm Please stand by. Your program is about to begin.

If you need assistance during your conference today, please press 0.

Good afternoon and thank you for joining Zebra's 2nd quarter, 2025 Financial Results and corporate Update conference call.

Today's call is being recorded and will be available via the investor relations section of the company's website later today.

The host for today's call is Nicole Osher, Deborah's Vice President of investor relations and corporate communications.

Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
-----------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.